We are analyzing https://link.springer.com/article/10.1007/s11926-012-0271-5.

Title:
Cardiovascular Disease and Rheumatoid Arthritis: An Update | Current Rheumatology Reports
Description:
Patients with rheumatoid arthritis (RA) suffer significantly increased cardiovascular (CV) morbidity and mortality, when compared with the general population. Both traditional CV risk factors and high levels of systemic inflammation have been linked to the increased CV risk in RA patients, but significant uncertainty remains regarding the mechanisms through which these factors contribute to CV disease (CVD). In addition, ongoing questions remain regarding how best to identify RA patients at high risk for CVD and what primary and secondary prevention strategies are effective at influencing CV outcome. The present review summarizes recent research in this field.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

arthritis, article, google, scholar, rheumatoid, pubmed, cas, patients, rheum, cardiovascular, risk, disease, ann, dis, factors, study, lipoprotein, atherosclerosis, lipid, mortality, van, charlesschoeman, inflammation, myocardial, necrosis, rheumatology, increased, high, acute, infarction, res, cholesterol, rheumatol, density, factor, coronary, treatment, systemic, events, carotid, hama, hdl, navab, tocilizumab, privacy, cookies, content, traditional, levels, access,

Topics {✒️}

travel/accommodations expenses covered/reimbursed month download article/chapter disease-modifying antirheumatic drugs platelet activating factor-acetylhydrolase increased coronary-artery atherosclerosis high-density lipoprotein loses key cardiovascular-related comorbidities carotid intima-media thickness apolipoprotein-related mortality risk article charles-schoeman high-density lipoprotein function christina charles-schoeman anti-tnf therapy ldl-derived oxidized phospholipids soluble ve-cadherin eular evidence-based recommendations traditional risk factors low-density lipoprotein high density lipoproteins high-density lipoproteins gonzalez-gay ma population-based cohort study full article pdf acute coronary syndromes cardiovascular risk factors high-density lipoprotein van lenten bj rheumatoid diseases de beer fc privacy choices/manage cookies low disease activity dixon wg high disease activity actual cardiovascular risk o'leary dh altered protein cargo acute coronary syndrome intima-media thickening rheumatology biologics register inflammatory response induced interleukin-6 receptor antagonist 5-fold increased risk van der velde cardiovascular risk management increased cv risk de llera-moya related subjects van den oever van halm vp van krugten mv

Questions {❓}

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
Is small artery elasticity decreased prior to intima-media thickening in patients with longstanding rheumatoid arthritis?
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?
What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cardiovascular Disease and Rheumatoid Arthritis: An Update
         description:Patients with rheumatoid arthritis (RA) suffer significantly increased cardiovascular (CV) morbidity and mortality, when compared with the general population. Both traditional CV risk factors and high levels of systemic inflammation have been linked to the increased CV risk in RA patients, but significant uncertainty remains regarding the mechanisms through which these factors contribute to CV disease (CVD). In addition, ongoing questions remain regarding how best to identify RA patients at high risk for CVD and what primary and secondary prevention strategies are effective at influencing CV outcome. The present review summarizes recent research in this field.
         datePublished:2012-07-12T00:00:00Z
         dateModified:2012-07-12T00:00:00Z
         pageStart:455
         pageEnd:462
         sameAs:https://doi.org/10.1007/s11926-012-0271-5
         keywords:
            Rheumatoid arthritis
            Cardiovascular disease
            Atherosclerosis
            Morbidity
            Mortality
            Risk factors
            Inflammation
            Therapy
            Rheumatology
         image:
         isPartOf:
            name:Current Rheumatology Reports
            issn:
               1534-6307
               1523-3774
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Christina Charles-Schoeman
               affiliation:
                     name:UCLA
                     address:
                        name:Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cardiovascular Disease and Rheumatoid Arthritis: An Update
      description:Patients with rheumatoid arthritis (RA) suffer significantly increased cardiovascular (CV) morbidity and mortality, when compared with the general population. Both traditional CV risk factors and high levels of systemic inflammation have been linked to the increased CV risk in RA patients, but significant uncertainty remains regarding the mechanisms through which these factors contribute to CV disease (CVD). In addition, ongoing questions remain regarding how best to identify RA patients at high risk for CVD and what primary and secondary prevention strategies are effective at influencing CV outcome. The present review summarizes recent research in this field.
      datePublished:2012-07-12T00:00:00Z
      dateModified:2012-07-12T00:00:00Z
      pageStart:455
      pageEnd:462
      sameAs:https://doi.org/10.1007/s11926-012-0271-5
      keywords:
         Rheumatoid arthritis
         Cardiovascular disease
         Atherosclerosis
         Morbidity
         Mortality
         Risk factors
         Inflammation
         Therapy
         Rheumatology
      image:
      isPartOf:
         name:Current Rheumatology Reports
         issn:
            1534-6307
            1523-3774
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Christina Charles-Schoeman
            affiliation:
                  name:UCLA
                  address:
                     name:Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Rheumatology Reports
      issn:
         1534-6307
         1523-3774
      volumeNumber:14
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:UCLA
      address:
         name:Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Christina Charles-Schoeman
      affiliation:
            name:UCLA
            address:
               name:Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(202)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.94s.

LINK . SPRINGER . COM {}